Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 11 | 2016 | 1309 | 0.590 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 5 | 2016 | 1622 | 0.480 |
Why?
|
| Patient Positioning | 1 | 2014 | 322 | 0.400 |
Why?
|
| Radiometry | 1 | 2014 | 800 | 0.330 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 806 | 0.300 |
Why?
|
| Photons | 6 | 2016 | 587 | 0.240 |
Why?
|
| Radiotherapy Dosage | 11 | 2019 | 2876 | 0.200 |
Why?
|
| Meningioma | 4 | 2019 | 1209 | 0.180 |
Why?
|
| Meningeal Neoplasms | 4 | 2019 | 1241 | 0.170 |
Why?
|
| Cranial Irradiation | 2 | 2019 | 401 | 0.170 |
Why?
|
| Brain Neoplasms | 4 | 2019 | 8829 | 0.170 |
Why?
|
| Radiotherapy, High-Energy | 2 | 2015 | 228 | 0.170 |
Why?
|
| Hypopituitarism | 1 | 2019 | 254 | 0.140 |
Why?
|
| Immobilization | 1 | 2014 | 236 | 0.110 |
Why?
|
| Neuroma, Acoustic | 3 | 2016 | 450 | 0.110 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2016 | 1679 | 0.100 |
Why?
|
| Radiation Dosage | 3 | 2016 | 1927 | 0.090 |
Why?
|
| Motion | 1 | 2014 | 797 | 0.090 |
Why?
|
| Radiation Injuries | 4 | 2019 | 1178 | 0.090 |
Why?
|
| Cost Savings | 1 | 2015 | 925 | 0.090 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2009 | 44 | 0.080 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2009 | 94 | 0.080 |
Why?
|
| Radiotherapy, Conformal | 2 | 2009 | 548 | 0.080 |
Why?
|
| Hippocampus | 3 | 2006 | 3661 | 0.080 |
Why?
|
| Nelson Syndrome | 1 | 2007 | 20 | 0.080 |
Why?
|
| Radiotherapy | 1 | 2015 | 1525 | 0.080 |
Why?
|
| Glioma | 2 | 2019 | 3388 | 0.080 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2006 | 91 | 0.070 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2007 | 176 | 0.060 |
Why?
|
| Acromegaly | 1 | 2007 | 347 | 0.060 |
Why?
|
| Cell Survival | 1 | 2015 | 5872 | 0.060 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2006 | 234 | 0.060 |
Why?
|
| Cranial Nerves | 1 | 2003 | 101 | 0.060 |
Why?
|
| Heart | 1 | 2016 | 4462 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 14720 | 0.050 |
Why?
|
| Eye Diseases | 1 | 2006 | 670 | 0.050 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2009 | 895 | 0.050 |
Why?
|
| Visual Acuity | 1 | 2009 | 2520 | 0.050 |
Why?
|
| Protons | 4 | 2007 | 1126 | 0.050 |
Why?
|
| Apoptosis | 1 | 2015 | 9715 | 0.040 |
Why?
|
| Thyroid Function Tests | 1 | 2019 | 284 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2015 | 876 | 0.040 |
Why?
|
| Cost Allocation | 1 | 2016 | 51 | 0.030 |
Why?
|
| Lung | 1 | 2015 | 9826 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2006 | 3760 | 0.030 |
Why?
|
| Pituitary Gland | 1 | 2019 | 665 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 19862 | 0.030 |
Why?
|
| Models, Econometric | 1 | 2016 | 219 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2003 | 1882 | 0.030 |
Why?
|
| Organs at Risk | 1 | 2016 | 346 | 0.030 |
Why?
|
| Arteriovenous Malformations | 1 | 2016 | 396 | 0.030 |
Why?
|
| Treatment Outcome | 5 | 2014 | 62966 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2003 | 2924 | 0.030 |
Why?
|
| Cricetulus | 1 | 2015 | 817 | 0.030 |
Why?
|
| Female | 13 | 2019 | 379592 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2016 | 5385 | 0.030 |
Why?
|
| Markov Chains | 1 | 2016 | 969 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2006 | 9185 | 0.030 |
Why?
|
| Adenoma | 2 | 2016 | 2168 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2007 | 35342 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2016 | 1254 | 0.020 |
Why?
|
| Cricetinae | 1 | 2015 | 2471 | 0.020 |
Why?
|
| Humans | 17 | 2019 | 742088 | 0.020 |
Why?
|
| Necrosis | 2 | 2006 | 1643 | 0.020 |
Why?
|
| Models, Economic | 1 | 2015 | 713 | 0.020 |
Why?
|
| Catheterization | 1 | 2016 | 1468 | 0.020 |
Why?
|
| Gadolinium | 2 | 2006 | 951 | 0.020 |
Why?
|
| Middle Aged | 11 | 2019 | 213127 | 0.020 |
Why?
|
| Adult | 11 | 2019 | 213712 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2003 | 4029 | 0.020 |
Why?
|
| Brain Diseases | 1 | 1999 | 1554 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2006 | 8300 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2016 | 1183 | 0.020 |
Why?
|
| Male | 14 | 2019 | 349538 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 20774 | 0.020 |
Why?
|
| Pituitary Neoplasms | 1 | 2016 | 1340 | 0.020 |
Why?
|
| Bromocriptine | 1 | 2007 | 111 | 0.020 |
Why?
|
| Growth Hormone-Secreting Pituitary Adenoma | 1 | 2007 | 45 | 0.020 |
Why?
|
| Adolescent | 5 | 2019 | 85649 | 0.020 |
Why?
|
| Octreotide | 1 | 2007 | 145 | 0.020 |
Why?
|
| Orbital Neoplasms | 1 | 2009 | 225 | 0.020 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2016 | 1162 | 0.020 |
Why?
|
| Follow-Up Studies | 5 | 2009 | 39004 | 0.020 |
Why?
|
| Retrospective Studies | 6 | 2019 | 77098 | 0.020 |
Why?
|
| Neoplasms | 1 | 2015 | 21596 | 0.020 |
Why?
|
| Growth Hormone | 1 | 2007 | 703 | 0.020 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 57683 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 2004 | 15244 | 0.020 |
Why?
|
| Child | 4 | 2019 | 77478 | 0.020 |
Why?
|
| Rats | 3 | 2006 | 24265 | 0.010 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2003 | 377 | 0.010 |
Why?
|
| Remission Induction | 1 | 2007 | 2384 | 0.010 |
Why?
|
| Benzoxazines | 1 | 2003 | 301 | 0.010 |
Why?
|
| Oxazines | 1 | 2003 | 298 | 0.010 |
Why?
|
| Aged | 5 | 2019 | 162944 | 0.010 |
Why?
|
| Vision Disorders | 1 | 2009 | 1057 | 0.010 |
Why?
|
| Brachytherapy | 1 | 2009 | 1246 | 0.010 |
Why?
|
| Coronary Disease | 1 | 2016 | 6078 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2003 | 565 | 0.010 |
Why?
|
| Patient Satisfaction | 2 | 2003 | 3391 | 0.010 |
Why?
|
| Electrophysiology | 1 | 2003 | 1309 | 0.010 |
Why?
|
| Cell Line | 1 | 2015 | 15994 | 0.010 |
Why?
|
| Supratentorial Neoplasms | 1 | 2001 | 160 | 0.010 |
Why?
|
| Life Tables | 1 | 2000 | 370 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2007 | 1825 | 0.010 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2006 | 798 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2007 | 2014 | 0.010 |
Why?
|
| Quality of Life | 2 | 2016 | 12730 | 0.010 |
Why?
|
| Age Factors | 1 | 2016 | 18355 | 0.010 |
Why?
|
| Particle Accelerators | 1 | 1999 | 173 | 0.010 |
Why?
|
| Young Adult | 2 | 2019 | 56350 | 0.010 |
Why?
|
| Biophysical Phenomena | 1 | 1999 | 327 | 0.010 |
Why?
|
| Animals | 5 | 2015 | 168561 | 0.010 |
Why?
|
| Survival Analysis | 2 | 2001 | 10248 | 0.010 |
Why?
|
| Biophysics | 1 | 1999 | 383 | 0.010 |
Why?
|
| Biotechnology | 1 | 1999 | 278 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2007 | 6534 | 0.010 |
Why?
|
| Algorithms | 1 | 2016 | 13853 | 0.010 |
Why?
|
| Memory | 1 | 2003 | 2163 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2000 | 1269 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 1999 | 921 | 0.010 |
Why?
|
| Survival Rate | 1 | 2006 | 12773 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 4029 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 11363 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2000 | 4839 | 0.010 |
Why?
|
| Risk Factors | 1 | 2016 | 72145 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2000 | 8621 | 0.000 |
Why?
|
| United States | 1 | 2015 | 69693 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 2004 | 18006 | 0.000 |
Why?
|
| Proportional Hazards Models | 1 | 2000 | 12344 | 0.000 |
Why?
|
| Prospective Studies | 1 | 2001 | 53187 | 0.000 |
Why?
|
| Brain | 1 | 2003 | 26343 | 0.000 |
Why?
|
Concepts
(132)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(34)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_